12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALN-TTRsc: Interim Phase I data

Interim data from 12 healthy volunteers in the multiple ascending-dose cohorts of a double-blind, U.K. Phase I trial showed that 10 subcutaneous injections of 2.5, 5 and 10 mg/kg ALN-TTRsc each led to significant knockdown of serum TTR protein levels vs. placebo. Specifically, mean TTR knockdown was 58.2% (p<0.01) in the 2.5 mg/kg dose arm, 87.5% (p<0.001) in the 5 mg/kg dose arm and 92.4% (p<0.001) in the 10 mg/kg dose...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >